|
|
|
- うまじ ごみぶち
- 9 years ago
- Views:
Transcription
1
2
3 20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J
4
5
6
7
8
9
10 Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas ofthe head and neck. J Clin Oncol 2004;22: Suntharalingam M et al. The use ofcarboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000; 47:49-56 Hitt R et ai. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by.chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005; 23: Gibson MK et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck an intergroup trial of the Eastern
11
12
13 b'-> XUIN l35mg/m2 tj,.> 2.Ol-s.oxULN 90mg/m2
14
15
16
17 mg;/m, I F+Ffi,Rffi
18
19
20
21 l) Centers for Medicare & Medicaid Services 2) Garden AS et al. Preliminary results of ltadiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chanotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004; 22: 2856:2864 3) Suntharalingam M et al. The use ofcarboplatin and paclitaxel wittr daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000; 47: ) Hitt R et ai. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplati4 and fluorolracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005',23: ) Gibson MK et ai. Randomized phase III evaluation ofcisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck an intergroup trial of the Eastem
22
23
24 i meldL
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 0.4ms
44
45
46
47
48
49
50
51
52
53
54
55
56 Amnicillin in the treatment of bacterial meninsitis P- C. Fleminng et al
57 Ampicillin compared with penicillin and chloramphenicol combined in the treatrnent of bacterial menineitis N. l. Girgis, et al.
58 Ampicillin-Cloxacillin in purulent meningitis Ampicillin dosage in bacterial meningitis with special reference to Haemophilus influenzae Greene G.R.. et al.
59 Lgng-acting chloramphenicol versus intravenous ampicillin for treatment ofbacterial menineitis A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in l3 16 cases of suspected sepsis in the newborn
60 Letters to the editor: Neonatal sepsis in Turkey: the comparison between penicillin plus aminoslvcoside and amnicillin olus third-seneration ceohalo.smrin chemothemnies Itv= GokalpAS and OguzA Ranodomized trial using piperacillin versus ampicillin and amikacin for treatment of Dremature neonates with risk factors for seosis O. Hammerberg, et al
61 Comparison between the combination of azlocillin-gentamicin and ampicillin-gentamicin in the treatment of a nursery population 4 71-/V D. Fogel, et al Effectiveness of ampicillin and combination of penicillin and chlorarnphenicol in the treatrnent of oneumonias: randomized controlled fiial N.Deivanayagam, el al
62 Chloramphenicol versus ampiiillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomized controlled rial (SPEAR studv) Rai Asghar, et al
63 (me n i n g i t i s) (sepsis)
64
65
66
67
68
69 50mg/kg A 12 ffiff,:& l. i+cks-zt a
70
71
72 l00mg/kg 50m94(g
73
74
75
76
77
78
79
80
81
82
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
untitled
260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...
untitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- [email protected] http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
PowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
日本消化器外科学会教育集会
Medical oncology T4N4M1 I 1T4 T4 T4 T4 1 T4 down-staging T4 40Gy 1 2820 R0 down-staging R0 2 T440Gy 20Gy 3 T460Gy 4 T4 down-staging T4 43 5 1511 R0 T4 1 T436Gy 6 30 18 R0 T4 1 11 3 R0 Salvage T4 Lerut
一般社団法人 日本感染症学会 第89回総会資料
Longitudinal surveillance of Haemophilus influenzae isolates from pediatric patients with meningitis throughout Japan, 2000 2011 Journal of Infection and Chemotherapy Vol.19No.1 p34-41kimiko Ubukata Long-term
) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
J. Jpn. Stomatol. Soc. 39(1) : , January, 1990 Clinical and histopathological studies of combination therapy with Cisplatin and Peplomycin (PP t
J. Jpn. Stomatol. Soc. 39(1) : 175183, January, 1990 Clinical and histopathological studies of combination therapy with Cisplatin and Peplomycin (PP therapy) for the carcinoma of the tongue Iwai TOHNAI,
化学療法
第 60 回 医 療 者 がん 研 修 会 2015/9/17 もっと 知 りたい 膀 胱 癌 治 療 尿 管 癌 膀 胱 癌 の 化 学 療 法 広 島 市 立 広 島 市 民 病 院 泌 尿 器 科 副 部 長 弓 狩 一 晃 泌 尿 器 科 での 化 学 療 法 経 尿 道 的 投 与 経 静 脈 動 脈 的 投 与 膀 胱 癌 治 療 1 表 在 癌 経 尿 道 的 膀 胱 腫 瘍 切 除
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
MV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO
乳がん患者の放射線皮膚炎に対するスキンケアの指導の実際 がん放射線療法看護認定看護師とがん放射線治療に携わる看護師との比較 Educating practice of skin care for radiodermatitis of breast cancer patients: Comparison of the nurses with certified nurse in radiation therapy
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
履 歴 書
,,,,,, Carboplatin and Monthly Paclitaxel Carboplatin and Weekly Paclitaxel 8(1), 25-34 (2006) Masayoshi KOINUMA, Takahisa YAMANASHI, Miwako KAMEI, Makoto SHIRAGAMI, The realities and Medical Expense of
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
untitled
19CRC/2009.8.8-9 T0 T1 T2 T3 T4 M0 N0 M1 19CRC 2009.8.8 1 2 N1 N2 N3 Stage 0 Stage I Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIC Stage IV Tis 3 4 5 6 1 19CRC/2009.8.8-9 7 8 Subtype of Breast Cancer
The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Fig. 1 Method of SRCA Table 1 Drug dose and treatment schedule in SRCA Table 2 Results of SRCA for renal cell carcinomas * Histological grading of the
SUBRENAL CAPSULE ASSAY FOR CHEMOSENSITIVITY TEST OF URINARY TRUCT CANCERS Jun Hasegawa, Yoshio Yamanaka, Kezutaka Horiuchi and Masao Akimoto Department of Urology, Nippon Medical School (Director: Prof.
untitled
Japan College of Social Work 01 Japan College of Social Work Profile Contents Japan College of Social Work 02 01 Case 02 Case 03 Case 04 Case 05 Case 03 Japan College of Social Work Japan College of Social
orororor oror CINAHL breast cancerhormonal therapyorendocrine therapyortamoxifenorgoserelinside effectorsymptomexperien
72017 3 資料 内分泌療法を受けている乳がん患者の苦痛体験に関する文献検討 A Literature Review regarding Distress Experienced by Breast Cancer Patients Undergoing Endocrine Therapy 四方文子 1), 鈴木久美 2) Ayako Shikata 1),Kumi Suzuki 2) キーワード
2
1 2 3 15 4 1 15 1 31 3 15 1 162 272 CPA 46 28 CPA 1 CPA 4 CPA 5 a. ( ) ACLS 15 5 17 b. 1 12 c. 25 29 6 7 8 CPA CPA 1 CPA Randomized Controlled Trial, RCT RCT CPA CPA 1 Dr 9 CPA CPA 15 4 1 15 1 31 CPA CPA
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
表 2 第 33 回日本外科学会 (1932 年 ) における瀬尾による食道癌宿題報告 ( 文献 8 より引用 ) 表 1 第 33 回日本外科学会 (1932 年 ) における瀬尾による食道癌宿題報告 ( 文献 8 より引用 ) 図 1 中山恒明先生による胸壁前食道胃吻合の図 ( 文献 10 より
食道癌治療の変遷 はじめに 50 2002 12 2007 食道外科の歴史 1913 13 1929 33 1932 12 50 95 1950 7 7 20 60 10 20 1960 45 表 2 第 33 回日本外科学会 (1932 年 ) における瀬尾による食道癌宿題報告 ( 文献 8 より引用 ) 表 1 第 33 回日本外科学会 (1932 年 ) における瀬尾による食道癌宿題報告 (
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
膵癌超音波診(案)
1 2 3 4 5 6 7 8 9 10 2009 7 6 2 a. invasive ductal carcinoma * 1 b. endocrine neoplasm c. Solid pseudopapillary neoplasm d. tumor producing pancreatitis * 2 * 1 invasive ductal carcinomas papillary adenocarcinoma
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Exif Viewer, DPOF Editor 使用説明書
Exif Viewer DP Editor 2 3 I 4 II III 5 I 6 I 7 I 8 I 9 I 10 I 11 I 12 I 13 I 14 I 15 I 16 I 17 I 18 I 19 I 20 I 21 I 22 I 23 I 24 25 I 26 I 27 I 28 I 29 I Windows 30 I 31 I 32 I 33 I 34 35 II II 36 II